epoetin alfa
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | RETACRIT | — | 2020-06-30 | fda.gov ↗ |
| Label expansions (5) | US (FDA) | EPOGEN/PROCRIT | — | 1993-04-01 – 2011-06-24 | fda.gov ↗ |
| Refused (EMA) | EU (EMA) | Abseamed | — | 2009-06-18 | europa.eu ↗ |
| Approved | EU (EMA) | NeoRecormon | — | 1997-07-16 | europa.eu ↗ |
| Approved | US (FDA) | EPOGEN/PROCRIT | — | 1989-06-01 | fda.gov ↗ |
Trials 292 · started per year
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2026-06-30 | Akebia Therapeutics | Results U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA akebia.com ↗
Worsening of hypertension was reported in 14% of VAFSEO and 17% of darbepoetin alfa patients. |
| 2023-12-09 | Bristol-Myers Squibb | Results Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023 bms.com ↗
New data confirm findings consistent with interim analysis, reaffirming superior efficacy and significantly longer durability of response with Reblozyl ® (luspatercept-aamt) compared to epoetin alfa |
| 2023-05-25 | Bristol-Myers Squibb | Results Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) bms.com ↗
Results from Phase 3 COMMANDS study, selected for ASCO’s official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent hemoglobin increase vs. epoetin alfa, including in clinically relevant subgroups |
| 2023-05-11 | Bristol-Myers Squibb | Results Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023 bms.com ↗
demonstrated highly statistically significant and clinically meaningful improvement in patients with anemia associated with very low- to intermediate-risk myelodysplastic syndromes |
| 2022-04-25 | Zydus Lifesciences Limited | Results Zydus announces publication of DREAM-ND and DREAM-D Phase 3 trials of Desidustat in American Journal of Nephrology zyduslife.com ↗
in the Epoetin group the mean baseline haemoglobin level was 9.46 g/dL which improved to 10.32 g/dL |
| 2018-05-15 | Pfizer | Regulatory Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA pfizer.com ↗
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT® (epoetin alfa-epbx), a biosimilar to Epogen® and Procrit® (epoetin alfa)1, for all indications of the reference product. |
| 2017-05-25 | Pfizer | Regulatory FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications pfizer.com ↗
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Company’s proposed epoetin alfa biosimilar across all indications. |
| 2017-05-01 | Xenetic Biosciences, Inc. | Results Xenetic Biosciences Presents Case Study of PolyXen™ Platform Technology at the 13th Annual Protein Engineering Summit (PEGS) Boston xeneticbio.com ↗
Case study demonstrates that polysialylated erythropoietin remained structurally intact, and physiologically active with an increased half-life in human circulation |
| 2016-04-08 | Novartis Pharmaceuticals | Regulatory Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indication novartis.com ↗
Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit's ® (epoetin alfa) nephrology indication*. |
| 2012-11-10 | Merck Sharp & Dohme LLC | Results Merck Reports New Phase III Analyses on Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy, Including Cirrhotic Patients merck.com ↗
SVR rates were generally similar regardless of when patients began ribavirin dose reduction, the number of steps of ribavirin dose reduction, or the lowest ribavirin dose of 400 to 1,000 mg/day received for at least 14 days for anemia management. |
| 2012-04-19 | Merck Sharp & Dohme LLC | Results Merck Reports Phase III Study Results Evaluating Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy merck.com ↗
The rates of SVR were 71 percent for both groups: those patients whose anemia was managed by ribavirin dose reduction (178/249) and those patients whose anemia was managed by the addition of erythropoietin (EPO) (178/251). |
All press releases naming this drug 11 releases
Evidence & citations 53 cited values
Every value below carries the sentence it was read from. 444 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epoetin alfa | “rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.” NCT03457701 ↗210“administration of single preoperative high dose shot of epoetin alfa (rhEPO) in a young (age \< 65 years of age) population undergoing cardiac surgery” NCT02802592 ↗ “HX575 (biosimilar epoetin alfa) was approved in Europe in 2007 for the treatment of chronic kidney disease (CKD)-related anemia.” PMID 29084409 ↗ Oct 2017 “epoetin alfa if they were receiving hemodialysis or darbepoetin alfa if they were receiving peritoneal dialysis” PMID 34739194 ↗ Nov 2021 “Epoetin alfa (Binocrit, Sandoz, Poland) given intravenously when Hb \<120 g/L, dosed by a study subject weight:” NCT06670963 ↗ “Epoetin alfa (EPOGEN), Methoxy polyethylene glycol-epoetin beta (Mircera), or Darbepoetin alfa (Aranesp)” NCT06520826 ↗ “PROCRIT (epoetin alfa, a glycoprotein that stimulates red blood cell production)” NCT00267007 ↗ “PROCRIT (Epoetin alfa) is a brand of recombinant human erythropoietin (rHuEPO).” NCT00337935 ↗ “Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection” NCT00869856 ↗ “Epoetin alfa may cause the body to make more red blood cells.” NCT00258440 ↗ “Epoetin alfa, a well established drug to treat renal anemia” NCT00322413 ↗ |
| Known as | Binocrit | “Epoetin alfa (Binocrit, Sandoz, Poland) given intravenously when Hb \<120 g/L, dosed by a study subject weight:” NCT06670963 ↗1“Binocrit” NCT04588311 ↗ |
| Known as | Brand name of Erythropoietin: Espogen (made by LG Life Science) | “Brand name of Erythropoietin: Espogen (made by LG Life Science)” NCT01193660 ↗ |
| Known as | EPIAO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02522975 ↗ |
| Known as | EPO | “This therapy will consist of hCG (3 once-daily IM doses at 10,000 IU per dose, one day apart, on days 1, 3 and 5 of study participation), followed by a one day washout period...” NCT00362414 ↗38“This work was conducted to evaluate the effect of early intervention with epoetin alfa (EPO) on transfusion requirements, hemoglobin level (Hb), quality of life (QOL) and to...” PMID 15953714 ↗ Jul 2005 “Erythropoietin (EPO) is approved by the FDA to treat anemia and has comprehensive preclinical data supporting its neuroprotective and neuroregenerative efficacy following...” NCT02226848 ↗ “Numerous preclinical findings and a clinical pilot study suggest that recombinant human erythropoietin (EPO) provides neuroprotection that may be beneficial for the treatment...” PMID 19834012 ↗ Oct 2009 “PURPOSE: An open-label, noninferiority study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat anemia in patients receiving chemotherapy for...” PMID 26858335 ↗ Feb 2016 “Erythropoietin (EPO) is a growth factor that promotes angiogenesis and bone regeneration by stimulating osteoblastic differentiation and by inhibiting osteoclastic resorption.” NCT06513039 ↗ “The diabetic foot ulcer (DFU) is a major disabling complication of diabetes mellitus. Growing evidence suggests that topical erythropoietin (EPO) can promote wound healing.” PMID 33504262 ↗ Apr 2021 “Erythropoietin (EPO) is a naturally occuring hormone which regulates the body's response to lack of oxygen and controls the number of red cells in the blood.” NCT00149058 ↗ “Erythropoietin (EPO) is a cytokine originally identified for its role in erythropoiesis and more recently shown to be produced in the central nervous system.” NCT00945789 ↗ “Erythropoietin (Epo) is a cytokine with remarkable neuroprotective and neuroregenerative effects demonstrated in animal models of neonatal brain injury.” NCT02811263 ↗ “To determine the safety and pharmacokinetics of erythropoietin (Epo) given in conjunction with hypothermia for hypoxic-ischemic encephalopathy (HIE).” PMID 23008465 ↗ Sep 2012 |
| Known as | EPO HEXAL | “HX575, EPO HEXAL” NCT00701714 ↗1“HX575, EPO Hexal” NCT00869856 ↗ |
| Known as | EPO-beta | “high doses of epoetin beta (EPO-beta)” PMID 20642691 ↗ Jul 2010 |
| Known as | EPO-α | “On the basis of promising animal data, this study evaluated any potential benefits of erythropoietin-alfa (EPO-α) given intra-arterially at the time of reperfusion of renal...” PMID 22745272 ↗ Jun 2012 |
| Known as | Epoetin | “In this noninferiority trial, we compared daprodustat administered three times weekly with epoetin alfa (epoetin) in patients on prevalent hemodialysis switching from a prior...” PMID 35918106 ↗ Aug 202212“Standard of care treatment for renal anemia, typically involving administration of erythropoiesis-stimulating agents (ESAs, e.g., epoetin, darbepoetin) and/or intravenous iron...” NCT06903559 ↗ “Standard of care treatment for renal anemia, typically involving administration of erythropoiesis-stimulating agents (ESAs, e.g., epoetin, darbepoetin) and/or intravenous iron...” NCT06917950 ↗ “Erythropoietin (Epoetin 4000 IU)” NCT07296146 ↗ |
| Known as | Epoetin alfa DT | “To determine whether Epoetin alfa manufactured by a roller bottle technology (Epoetin alfa RB) and Epoetin alfa manufactured by a deep tank process (Epoetin alfa DT) have a...” NCT00156962 ↗ |
| Known as | Epoetin alfa HEXAL | “Recombinant human EPO (Epoetin alfa HEXAL®) will be given as an i.v. bolus injection on days 1, 2 and 3.” NCT01962571 ↗ |
| Known as | Epoetin alfa RB | “To determine whether Epoetin alfa manufactured by a roller bottle technology (Epoetin alfa RB) and Epoetin alfa manufactured by a deep tank process (Epoetin alfa DT) have a...” NCT00156962 ↗ |
| Known as | epoetin alfa-epbx | “Low dose epoetin alfa-epbx recombinant (400 units/kg) subcutaneously or intravenously three times weekly on Monday, Wednesday, and Friday until age 33-6/7wk.” NCT05617833 ↗2“epoetin alfa-epbx (RetacritTM; a biosimilar to US-licensed Epogen®/Procrit®)” PMID 30196301 ↗ Sep 2018 “Epoetin alfa-epbx is a biosimilar to the reference product, epoetin alfa.” PMID 32734207 ↗ Aug 2019 |
| Known as | Epoetin alfa/beta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02064426 ↗ |
| Known as | epoetin alpha | “40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.” NCT03339596 ↗13“Patients were assigned to 12 weekly injections of subcutaneous epoetin alpha or placebo, targeting Hgb levels between 120 and 140 g/L.” PMID 17312332 ↗ Feb 2007 “Six male and six female subjects received recombinant human epoetin alpha (Erypo®) intravenously (300 U/kg).” PMID 22098110 ↗ Nov 2011 “associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).” NCT02496377 ↗ “Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)” NCT00267007 ↗ “Epoetin alpha” NCT00513240 ↗ |
| Known as | Epoetin beta | “We aimed to compare the effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times...” PMID 17950856 ↗ Oct 200745“Epoetin alfa may be administered in either the United States (US) or Japan; epoetin beta will only be administered in Japan.” NCT01975818 ↗ “Erythropoietin (Epoetin-beta, NeoRecormon®)” NCT01584921 ↗ “30 000 IU Neorecormon â (epoetin beta) s.c.” NCT00145652 ↗ “Erythropoietin (Epoetin beta)” NCT01889056 ↗ “Drug: Epoetin beta” NCT02876211 ↗ |
| Known as | Epoetin Hospira | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01628107 ↗ |
| Known as | Epoetin Omega | “Epoetin Omega, that differs from Epoetin alfa in the sugar moiety of the molecule” NCT00322413 ↗ |
| Known as | Epoetin Zeta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03598582 ↗ |
| Known as | epoetin β | “either recombinant human erythropoietin (rHuEPO; epoetin-β, 9 IU/kg, n = 24, (12 females, 12 males)) or placebo (0,9% NaCl, n = 24, (12 females, 12 males)) three times per week...” NCT04965961 ↗5“either recombinant human erythropoietin (rHuEPO; epoetin-β, 9 IU/kg, n = 24, (12 females, 12 males)) or placebo (0,9% NaCl, n = 24, (12 females, 12 males)) three times per week...” NCT04965961 ↗ “azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.” PMID 27229713 ↗ May 2016 “With Epoetin β Support (450 IU/kg/Week)” NCT00356486 ↗ |
| Known as | epoetin-α | “HX575 was approved in the European Union in August 2007 as the first-ever biosimilar epoetin-α product.” PMID 22732334 ↗ Jul 2012 |
| Known as | EPOGEN | “Epoetin alfa (EPOGEN), Methoxy polyethylene glycol-epoetin beta (Mircera), or Darbepoetin alfa (Aranesp)” NCT06520826 ↗1“EPOGEN® (epoetin alfa)” NCT04073849 ↗ |
| Known as | EPORON | “EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.” NCT02580006 ↗ |
| Known as | EPORON PFS 4000 IU/0.4 mL (Erythropoietin alfa 4000 IU) | “EPORON PFS 4000 IU/0.4 mL (Erythropoietin alfa 4000 IU)” NCT02580006 ↗ |
| Known as | Epoétine beta | “Study Treatment: Neorecormon® (Epoétine beta) under cutaneous injection” NCT00396435 ↗ |
| Known as | eprax | “Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).” NCT04469777 ↗ |
| Known as | Eprex | “A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Impact of Maintaining Hemoglobin Using Eprex (Epoetin Alfa) in Metastatic Breast Carcinoma Subjects...” NCT00211133 ↗6“The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.” NCT00002022 ↗ “EPREX INJ. 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.” NCT02580006 ↗ “subcutaneous Eporon versus Epoetin Alfa (Eprex)” NCT03521713 ↗ “50 UI/kg of Epoetin alpha (Eprex)” NCT01695759 ↗ “Erythropoetin (rHuEPO, EPREX®)” NCT00478517 ↗ “Eprex” NCT04588311 ↗ |
| Known as | Eritromax | “50 UI/kg of Epoetin alpha (Eritromax)” NCT01695759 ↗ |
| Known as | Erypo | “Six male and six female subjects received recombinant human epoetin alpha (Erypo®) intravenously (300 U/kg).” PMID 22098110 ↗ Nov 2011 |
| Known as | Erythropoetin | “Erythropoetin (Neorecormon) and ATRA” NCT00437450 ↗7“Erythropoetin (EPO)” NCT01384565 ↗ |
| Known as | erythropoietin | “This is a prospective, randomized multicenter phase III clinical trial designed to evaluate the safety and activity of comparison between Erythropoietin and Erythropoietin...” NCT00804050 ↗109“Erythropoietin (EPO) is approved by the FDA to treat anemia and has comprehensive preclinical data supporting its neuroprotective and neuroregenerative efficacy following...” NCT02226848 ↗ “Erythropoietin has antiapoptotic, antiexcitatory, and anti-inflammatory properties to prevent neuronal cell death in animal models, and improves neurodevelopmental outcomes in...” PMID 23102686 ↗ Oct 2012 “treatment with epoetin alfa (recombinant human erythropoietin) on anemia related QoL and anemia in non-small cell lung cancer patients with advanced stage disease and...” NCT00310232 ↗ “This study evaluates the effect of repeated low-dose erythropoietin (EPO) treatment on necrotizing enterocolitis (NEC) in very preterm infants.” NCT03919500 ↗ “The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.” NCT00002022 ↗ “Granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) will be injected for a total of 4 days” NCT06364150 ↗ “adding Erythropoietin (EPO) in granulocyte-colony stimulating factor (G-CSF)-mobilized stem cell therapy” PMID 29962032 ↗ Aug 2018 “administration of erythropoietin (EPO) with intravenous iron supplementation” PMID 39022429 ↗ Jun 2024 “30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation” NCT00362414 ↗ “Erythropoietin/Isosorbide dinitrate loaded cryogel scaffold” NCT05671250 ↗ |
| Known as | Erythropoietin beta | “Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy” NCT00875004 ↗ |
| Known as | erythropoietin-alfa | “On the basis of promising animal data, this study evaluated any potential benefits of erythropoietin-alfa (EPO-α) given intra-arterially at the time of reperfusion of renal...” PMID 22745272 ↗ Jun 20127“EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.” NCT02580006 ↗ “Biological: Erythropoietin alfa” NCT07025681 ↗ |
| Known as | Erythropoiétine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00180999 ↗ |
| Known as | HRE | “Previous studies at our Hospital have shown that high dose Human Recombinant Erythropoietin (HRE)effectively spares transfusions even when administered two days before surgery.” NCT01265680 ↗ |
| Known as | HrEPO | “Human Recombinant Erythropoietin (HrEPO) in Asphyxia Neonatorum: A Pilot Trial” NCT00945789 ↗ |
| Known as | human recombinant erythropoietin | “Human Recombinant Erythropoietin (HrEPO) in Asphyxia Neonatorum: A Pilot Trial” NCT00945789 ↗1“Drug: human recombinant erythropoietin” NCT00882466 ↗ |
| Known as | HX575 | “Eligible patients were switched from the comparator ERYPO®, to epoetin alfa HX575 Hexal AG in ratio 2:1 to be intravenously treated with HX575 in pre-filled syringes for 24...” NCT00666835 ↗6“Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.” NCT01576341 ↗ |
| Known as | HX575 epoetin alfa | “HX575 epoetin alfa” NCT00632125 ↗ |
| Known as | Neocormon | “Epoetin Beta (Neocormon®)” NCT00559195 ↗ |
| Known as | NeoRecormon | “Participants receive intravenous injections of 9 International Units per kg bodyweight epoetin-β (NeoRecormon, Roche, Mannheim, Germany) three times per week for four weeks on...” NCT04965961 ↗15“Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy” NCT00875004 ↗ “A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy” NCT02761642 ↗ “A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors” NCT02554942 ↗ “Erythropoietin (Epoetin-beta, NeoRecormon®)” NCT01584921 ↗ “30 000 IU Neorecormon â (epoetin beta) s.c.” NCT00145652 ↗ “Erythropoetin (Neorecormon) and ATRA” NCT00437450 ↗ “epoetin beta [NeoRecormon]” NCT00413101 ↗ “epoetin beta [NeoRecormon]” NCT00440063 ↗ “epoetin beta [NeoRecormon]” NCT00377481 ↗ “epoetin beta [NeoRecormon]” NCT00437723 ↗ |
| Known as | Procrit | “This was an open-label (doctors and patients knew which drug was being administered), non-randomized (patients were assigned to treatment), multi-center pilot study with the...” NCT00388336 ↗38“The primary objective of this study is to compare the change in hemoglobin (Hb) from study start to the end of the study between the every 2 week and the every 4 week dosing...” NCT00212875 ↗ “The purpose of this study is to evaluate the effectiveness and safety of less frequent dosing of PROCRIT (Epoetin alfa) in patients with anemia due to Chronic Kidney Disease...” NCT00307814 ↗ “The purpose of this study is to assess changes in physical function in elderly patients (\>= 65 years of age) with chronic anemia (Hb \<= 11.0 g/dL) due to anemia of unknown...” NCT00228995 ↗ “The purpose of this study is to evaluate the effectiveness of PROCRIT (Epoetin alfa) 80,000 Units given once weekly or 80,000 Units given once every two weeks in anemic...” NCT00446602 ↗ “The primary objective of this study is to describe how four different dosing regimens of PROCRIT (epoetin alfa) are utilized in patients with anemia due to non-dialysis chronic...” NCT00641589 ↗ “Epoetin Alfa (Procrit) is a manufactured form of a naturally occurring hormone that is given as an injection by a medical professional to stimulate the bone marrow's production...” NCT00337441 ↗ “Comparative Pharmacokinetic and Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Anemic Critically Ill Patients Randomized to One of Six Dose Regimens for 15 Days” NCT00210756 ↗ “Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy” NCT00255749 ↗ “Patients will receive injections of PROCRIT (Epoetin alfa) 60,000 Units (U) once weekly (QW) under the skin for up to 12 weeks (Initiation Phase)” NCT00338416 ↗ “The patients will receive subcutaneous (under the skin) injections of Epoetin alfa (PROCRIT) at one of the following dosing regimens:” NCT00210834 ↗ |
| Known as | PROCRIT | “The purpose of this study is to assess changes in physical function in elderly patients (\>= 65 years of age) with chronic anemia (Hb \<= 11.0 g/dL) due to anemia of unknown...” NCT00228995 ↗1“receiving weekly subcutaneous doses of Epoetin alfa (PROCRIT®) versus placebo” NCT00210795 ↗ |
| Known as | recombinant human erythropoietin | “The purpose of this study was to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) or placebo on anemia related quality-of-life and anemia...” NCT00364455 ↗7“This randomized trial assessed the effect of recombinant human erythropoietin (EPO) vs preoperative autologous donation (PAD) on postoperative vigor and handgrip strength in...” PMID 17400086 ↗ Apr 2007 “Numerous preclinical findings and a clinical pilot study suggest that recombinant human erythropoietin (EPO) provides neuroprotection that may be beneficial for the treatment...” PMID 19834012 ↗ Oct 2009 “either recombinant human erythropoietin (rHuEPO; epoetin-β, 9 IU/kg, n = 24, (12 females, 12 males)) or placebo (0,9% NaCl, n = 24, (12 females, 12 males)) three times per week...” NCT04965961 ↗ “the use of recombinant human erythropoietin (EPO) has also been proposed in cardiac surgery” NCT04141631 ↗ “One arm received recombinant human erythropoietin 4000 UI subcutaneously every other day” PMID 35279078 ↗ Mar 2022 “intravenous bolus of recombinant human erythropoietin (rhEPO, 50 U/kg)” PMID 20199815 ↗ Mar 2010 “Recombinant human erythropoietin (rHuEPO, epoetin alfa)” NCT03683810 ↗ |
| Known as | recombinant human erythropoietin alfa | “HX575 recombinant human erythropoietin alfa” NCT00701714 ↗ |
| Known as | Recormon | “receive either a single dose of EPO (Recormon, Roche, Epoetin beta) or saline intravenously before PCI.” NCT01364402 ↗ |
| Known as | rEpo | “In animal studies, recombinant Epo (rEpo) administration, even up to six hours after oxygen deprivation, reduced subsequent brain injury by 50% to 70%.” NCT00491413 ↗ |
| Known as | RetacritTM | “epoetin alfa-epbx (RetacritTM; a biosimilar to US-licensed Epogen®/Procrit®)” PMID 30196301 ↗ Sep 2018 |
| Known as | rhEPO | “This study evaluated the efficacy of combination therapy using allogeneic umbilical cord blood (UCB), a relatively safe therapeutic cell source, and recombinant human...” PMID 41456040 ↗ Dec 20254“Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300...” NCT01392612 ↗ “The objective of this study was to evaluate the protective effect of repeated low-dose recombinant human erythropoietin (rhEPO) in preterm infants with IVH.” PMID 33959935 ↗ May 2021 “This study aimed to determine whether recombinant human EPO (rhEPO) could protect against NEC in very preterm infants.” PMID 32771013 ↗ Aug 2020 “intravenous bolus of recombinant human erythropoietin (rhEPO, 50 U/kg)” PMID 20199815 ↗ Mar 2010 |
| Known as | rHuEPO | “The efficacy of recombinant human erythropoietin (rHuEPO) in sparing red blood cell (RBC) transfusions in children with hemolytic uremic syndrome related to Shiga...” PMID 35166922 ↗ Feb 20225“either recombinant human erythropoietin (rHuEPO; epoetin-β, 9 IU/kg, n = 24, (12 females, 12 males)) or placebo (0,9% NaCl, n = 24, (12 females, 12 males)) three times per week...” NCT04965961 ↗ “Since the release of the recombinant human erythropoietin (rhuEPO) at the beginning of the 90s, transfusions are less needed to treat anemia in chronic kidney disease patients.” NCT03401710 ↗ “Recombinant Human Erythropoietin (r-HuEPO) in the Prevention of Neurologic Sequelae From Malignant Spinal Cord Compression” NCT00220675 ↗ “Recombinant human erythropoietin (rHuEPO, epoetin alfa)” NCT03683810 ↗ “Erythropoetin (rHuEPO, EPREX®)” NCT00478517 ↗ |
| Action | Activate | “Its function is to stimulate the production of red blood cells in the bone marrow.” NCT00337935 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Erythropoietin” NCT00002255 ↗ |
| Route | Subcutaneous | “erythropoietin administered subcutaneously” NCT00002073 ↗ |